326 related articles for article (PubMed ID: 20515950)
1. Antitumor activity and immune response induction of a dual agonist of Toll-like receptors 7 and 8.
Wang D; Precopio M; Lan T; Yu D; Tang JX; Kandimalla ER; Agrawal S
Mol Cancer Ther; 2010 Jun; 9(6):1788-97. PubMed ID: 20515950
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and immunological activities of novel Toll-like receptor 7 and 8 agonists.
Kandimalla ER; Struthers M; Bett AJ; Wisniewski T; Dubey SA; Jiang W; Precopio M; Sun Z; Wang H; Lan T; Agrawal S; Casimiro DR
Cell Immunol; 2011; 270(2):126-34. PubMed ID: 21570062
[TBL] [Abstract][Full Text] [Related]
3. Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists.
Hamm S; Rath S; Michel S; Baumgartner R
J Immunotoxicol; 2009 Dec; 6(4):257-65. PubMed ID: 19848448
[TBL] [Abstract][Full Text] [Related]
4. Toll-like receptor 7 selective synthetic oligoribonucleotide agonists: synthesis and structure-activity relationship studies.
Lan T; Dai M; Wang D; Zhu FG; Kandimalla ER; Agrawal S
J Med Chem; 2009 Nov; 52(21):6871-9. PubMed ID: 19824640
[TBL] [Abstract][Full Text] [Related]
5. Dual or triple activation of TLR7, TLR8, and/or TLR9 by single-stranded oligoribonucleotides.
Forsbach A; Samulowitz U; Völp K; Hofmann HP; Noll B; Tluk S; Schmitz C; Wader T; Müller C; Podszuweit A; Lohner A; Curdt R; Uhlmann E; Vollmer J
Nucleic Acid Ther; 2011 Dec; 21(6):423-36. PubMed ID: 22196370
[TBL] [Abstract][Full Text] [Related]
6. Synthetic oligoribonucleotides containing arabinonucleotides act as agonists of TLR7 and 8.
Lan T; Bhagat L; Wang D; Dai M; Kandimalla ER; Agrawal S
Bioorg Med Chem Lett; 2009 Apr; 19(7):2044-7. PubMed ID: 19269175
[TBL] [Abstract][Full Text] [Related]
7. Stabilized immune modulatory RNA compounds as agonists of Toll-like receptors 7 and 8.
Lan T; Kandimalla ER; Yu D; Bhagat L; Li Y; Wang D; Zhu F; Tang JX; Putta MR; Cong Y; Trombino AF; Sullivan T; Agrawal S
Proc Natl Acad Sci U S A; 2007 Aug; 104(34):13750-5. PubMed ID: 17698957
[TBL] [Abstract][Full Text] [Related]
8. Synthetic oligoribonucleotides-containing secondary structures act as agonists of Toll-like receptors 7 and 8.
Lan T; Putta MR; Wang D; Dai M; Yu D; Kandimalla ER; Agrawal S
Biochem Biophys Res Commun; 2009 Aug; 386(3):443-8. PubMed ID: 19523922
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, purification, and characterization of oligoribonucleotides that act as agonists of TLR7 and/or TLR8.
Lan T; Kandimalla ER
Methods Mol Biol; 2011; 764():249-61. PubMed ID: 21748646
[TBL] [Abstract][Full Text] [Related]
10. Identification of High-Potency Human TLR8 and Dual TLR7/TLR8 Agonists in Pyrimidine-2,4-diamines.
Beesu M; Salyer AC; Brush MJ; Trautman KL; Hill JK; David SA
J Med Chem; 2017 Mar; 60(5):2084-2098. PubMed ID: 28146629
[TBL] [Abstract][Full Text] [Related]
11. Administration of a dual toll-like receptor 7 and toll-like receptor 8 agonist protects against influenza in rats.
Hammerbeck DM; Burleson GR; Schuller CJ; Vasilakos JP; Tomai M; Egging E; Cochran FR; Woulfe S; Miller RL
Antiviral Res; 2007 Jan; 73(1):1-11. PubMed ID: 16959331
[TBL] [Abstract][Full Text] [Related]
12. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
Wang D; Jiang W; Zhu F; Mao X; Agrawal S
Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
[TBL] [Abstract][Full Text] [Related]
13. Toll-like receptor 4, Toll-like receptor 7 and Toll-like receptor 9 agonists enhance immune responses against blood-stage Plasmodium chabaudi infection in BALB/c mice.
Gao W; Sun X; Li D; Sun L; He Y; Wei H; Jin F; Cao Y
Int Immunopharmacol; 2020 Dec; 89(Pt B):107096. PubMed ID: 33091818
[TBL] [Abstract][Full Text] [Related]
14. TLR7/8 agonists activate a mild immune response in rabbits through TLR8 but not TLR7.
Lai CY; Liu YL; Yu GY; Maa MC; Leu TH; Xu C; Luo Y; Xiang R; Chuang TH
Vaccine; 2014 Sep; 32(43):5593-9. PubMed ID: 25131730
[TBL] [Abstract][Full Text] [Related]
15. Identification of RNA sequence motifs stimulating sequence-specific TLR8-dependent immune responses.
Forsbach A; Nemorin JG; Montino C; Müller C; Samulowitz U; Vicari AP; Jurk M; Mutwiri GK; Krieg AM; Lipford GB; Vollmer J
J Immunol; 2008 Mar; 180(6):3729-38. PubMed ID: 18322178
[TBL] [Abstract][Full Text] [Related]
16. Signaling through TLR7 enhances the immunosuppressive activity of murine CD4+CD25+ T regulatory cells.
Forward NA; Furlong SJ; Yang Y; Lin TJ; Hoskin DW
J Leukoc Biol; 2010 Jan; 87(1):117-25. PubMed ID: 19843574
[TBL] [Abstract][Full Text] [Related]
17. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M
J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768
[TBL] [Abstract][Full Text] [Related]
18. Positive T cell co-stimulation by TLR7/8 ligands is dependent on the cellular environment.
Richardt-Pargmann D; Wechsler M; Krieg AM; Vollmer J; Jurk M
Immunobiology; 2011; 216(1-2):12-23. PubMed ID: 20542588
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
[TBL] [Abstract][Full Text] [Related]
20. Systemic cancer therapy with a small molecule agonist of toll-like receptor 7 can be improved by circumventing TLR tolerance.
Bourquin C; Hotz C; Noerenberg D; Voelkl A; Heidegger S; Roetzer LC; Storch B; Sandholzer N; Wurzenberger C; Anz D; Endres S
Cancer Res; 2011 Aug; 71(15):5123-33. PubMed ID: 21697281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
